Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb Company (BMY)
NYSE:BMY
BMY Stock Chart & Stats
$60.77
-$0.69(-1.21%)
At close: 4:00 PM EST
$60.77
-$0.69(-1.21%)
Day’s Range― - ―
52-Week Range$42.52 - $63.33
Previous CloseN/A
Volume3.98M
Average Volume (3M)12.31M
Market Cap
$123.71B
Enterprise Value$68.02B
Total Cash (Recent Filing)$16.50B
Total Debt (Recent Filing)$51.04B
Price to Earnings (P/E)17.6
Beta0.27
Next Earnings
Apr 30, 2026EPS Estimate
1.44Next Dividend Ex-DateN/A
Dividend Yield4.84%
Share Statistics
EPS (TTM)1.26
Shares Outstanding2,035,753,000
10 Day Avg. Volume14,933,255
30 Day Avg. Volume12,307,843
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)7.02
Price to Sales (P/S)2.37
P/FCF Ratio8.22
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue1.42
Enterprise Value/Gross Profit2.15
Enterprise Value/Ebitda4.56
Forecast
1Y Price Target
$59.89Price Target Upside-1.45% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)6.16
Revenue Forecast (FY)$46.03B
Bulls Say, Bears Say
Bulls Say
Commercial Traction Of Growth-stage DrugsAnalyst highlights accelerating commercial momentum for growth-stage medicines such as Reblozyl, Camzyos, and Breyanzi, which could drive sustained top-line expansion if market adoption continues.
Earnings BeatAnalyst notes the company reported revenue and adjusted earnings per share above expectations driven by strength across the growth portfolio, which could support a re-rating of the shares.
Eliquis Pricing BenefitAnalyst indicates recent pricing rule changes removed certain rebate and penalty liabilities for Eliquis, boosting cash generation and enhancing financial flexibility to fund growth initiatives.
Bears Say
Concentrated Clinical Readouts And Legacy UnderperformanceAnalyst highlights concentration of important clinical readouts and underperformance in some legacy products, creating uncertainty about whether new launches can fully offset declines and increasing execution risk.
Generic Competition RiskAnalyst warns that loss of exclusivity for the leading anticoagulant in major markets would erode revenue and cap long-term upside unless new protections or offsetting products emerge.
Higher Tax Rate Constraining EarningsAnalyst indicates adjusted earnings guidance was constrained by a higher tax rate, which limits reported earnings upside despite operational strength.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb Company’s price range in the past 12 months?
Bristol-Myers Squibb Company lowest stock price was $42.52 and its highest was $63.33 in the past 12 months.
What is Bristol-Myers Squibb Company’s market cap?
Bristol-Myers Squibb Company’s market cap is $123.71B.
When is Bristol-Myers Squibb Company’s upcoming earnings report date?
Bristol-Myers Squibb Company’s upcoming earnings report date is Apr 30, 2026 which is in 77 days.
How were Bristol-Myers Squibb Company’s earnings last quarter?
Bristol-Myers Squibb Company released its earnings results on Feb 05, 2026. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.226 by $0.034.
Is Bristol-Myers Squibb Company overvalued?
According to Wall Street analysts Bristol-Myers Squibb Company’s price is currently Overvalued.
Does Bristol-Myers Squibb Company pay dividends?
Bristol-Myers Squibb Company pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 4.84%. See more information on Bristol-Myers Squibb Company dividends here
What is Bristol-Myers Squibb Company’s EPS estimate?
Bristol-Myers Squibb Company’s EPS estimate is 1.44.
How many shares outstanding does Bristol-Myers Squibb Company have?
Bristol-Myers Squibb Company has 2,035,753,000 shares outstanding.
What happened to Bristol-Myers Squibb Company’s price movement after its last earnings report?
Bristol-Myers Squibb Company reported an EPS of $1.26 in its last earnings report, beating expectations of $1.226. Following the earnings report the stock price went up 3.297%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb Company?
Currently, no hedge funds are holding shares in BMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$59.89 (-1.45% Downside)
$59.89 (-1.45% Downside)
Blogger Sentiment
Bullish
BMY Sentiment 93%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 90%
Bearish news 10%
Bearish news 10%
Company Description
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
BMY Company Deck
BMY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial positive momentum: a high-growth portfolio delivering double-digit growth, multiple products achieving billion-dollar status, a robust near-term pipeline with numerous data catalysts, disciplined cost savings, and a strengthened balance sheet. Offsetting risks include LOE/generic pressures on the legacy portfolio (notably Eliquis over time), mix-driven margin pressure, one-time R&D charges, and the execution risk inherent in upcoming clinical readouts. Overall, the positives (strong commercial growth, pipeline depth, cost execution, and financial flexibility) outweigh the challenges.View all BMY earnings summariesBMY Revenue Breakdown
54.80% Growth Portfolio
45.20% Legacy Portfolio
BMY Stock 12 Month Forecast
Average Price Target
$59.89
▼(-1.45% Downside)
Technical Analysis
Ownership Overview
0.05% Insiders
19.69% Mutual Funds
6.15% Other Institutional Investors
47.30% Public Companies and Individual Investors